Assets

IBD98-M

IBD98-M

Steroid-sparing anti-Inflammatory mild to moderate UC
Oral, multi-layer coated pellet combines HA and mesalamine.
• Complete Mucosal healing 23.8%
• Anti-inflammation effects IBD98-M > 5-ASA
• Targeted colonic delivery

IBD98-M is developed by HylMusa™ platform for mild to moderate UC patients.
Mesalamine has been widely utilized for anti-inflammatory agent.
Sodium hyaluronate act as a protective barrier to the UC colon, and enhancing the efficacy of mesalamine, reduction of mesalamine dose and its associated toxicity.
• Mode of Action: Forms HA barrier over inflamed mucosa while delivering mesalamine locally
• Clinical Status: Phase IIa showed significant symptom relief with a reduced drug burden; Phase IIb/III in preparation
IBD98-M asset
250611 MPO
IBD98-M asset
250611 MPO
Specification
IBD98M, uses HylMusa™ to deliver mesalamine in a targeted, colon-specific manner. IBD98M demonstrated superior mucosal healing and anti-inflammatory efficacy compared to conventional mesalamine formulations.
Phase IIa clinical study: A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis
Preclinical studies: Combined Treatment with Hyaluronic Acid and Mesalamine Protects Rats from Inflammatory Bowel Disease Induced by Intracolonic Administration of Trinitrobenzenesulfonic Acid